ES2099736T3 - Utilizacion de derivados de la 15-deshidroxi-16-oxoprostaglandina en el tratamiento de las alergias. - Google Patents

Utilizacion de derivados de la 15-deshidroxi-16-oxoprostaglandina en el tratamiento de las alergias.

Info

Publication number
ES2099736T3
ES2099736T3 ES91303667T ES91303667T ES2099736T3 ES 2099736 T3 ES2099736 T3 ES 2099736T3 ES 91303667 T ES91303667 T ES 91303667T ES 91303667 T ES91303667 T ES 91303667T ES 2099736 T3 ES2099736 T3 ES 2099736T3
Authority
ES
Spain
Prior art keywords
dehydroxy
treatment
oxoprostaglandine
allergies
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91303667T
Other languages
English (en)
Inventor
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
R Tech Ueno Ltd
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Application granted granted Critical
Publication of ES2099736T3 publication Critical patent/ES2099736T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

UN USO DE UN COMPUESTO DE 15-DESHIDROXI-16-OXOPROSTAGLANDINA PARA LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE UNA ENFERMEDAD ALERGICA.
ES91303667T 1990-04-27 1991-04-24 Utilizacion de derivados de la 15-deshidroxi-16-oxoprostaglandina en el tratamiento de las alergias. Expired - Lifetime ES2099736T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11230390 1990-04-27
JP6132791 1991-03-01

Publications (1)

Publication Number Publication Date
ES2099736T3 true ES2099736T3 (es) 1997-06-01

Family

ID=26402368

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91303667T Expired - Lifetime ES2099736T3 (es) 1990-04-27 1991-04-24 Utilizacion de derivados de la 15-deshidroxi-16-oxoprostaglandina en el tratamiento de las alergias.

Country Status (10)

Country Link
EP (1) EP0454429B1 (es)
JP (1) JPH07103030B2 (es)
KR (1) KR970005173B1 (es)
AT (1) ATE148344T1 (es)
AU (1) AU639322B2 (es)
CA (1) CA2041240C (es)
DE (1) DE69124415T2 (es)
DK (1) DK0454429T3 (es)
ES (1) ES2099736T3 (es)
GR (1) GR3022706T3 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59305822D1 (de) * 1992-08-07 1997-04-17 Schering Ag Verwendung von prostanderivaten zur herstellung eines arzneimittels zur behandlung der chronischen polyarthritis
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
US20120270945A1 (en) * 2011-04-19 2012-10-25 Sucampo Ag Method for modulating cytokine activity
US20120277299A1 (en) * 2011-04-27 2012-11-01 Sucampo Ag Method for modulating ion transporter
WO2012176792A1 (ja) * 2011-06-21 2012-12-27 株式会社アールテック・ウエノ 炎症性疾患、アレルギー性疾患および自己免疫疾患用途のための医薬組成物
US20160228403A1 (en) * 2013-10-04 2016-08-11 Tohoku University Agent for preventing or ameliorating renal dysfunction

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644638A (en) * 1970-08-24 1972-02-22 American Home Prod Compositions and methods for relieving bronchial spasm with prostanoic acids and esters
US3836667A (en) * 1972-03-24 1974-09-17 Miles Lab Method of producing bronchodilation
GB1507211A (en) * 1975-02-14 1978-04-12 Ono Pharmaceutical Co Prostaglandin analogues
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
EP0153858A3 (en) * 1984-02-29 1985-12-11 The Upjohn Company The therapeutic use of prostaglandins
US4879285A (en) * 1986-08-22 1989-11-07 Royal North Shore Hospital And Area Health Service Fertility control
AU616502B2 (en) * 1988-04-22 1991-10-31 Medvet Science Pty. Ltd. Treatment of inflammatory disorders in humans
DE69025787T2 (de) * 1989-04-04 1996-10-31 Beiersdorf Ag Mittel zur Atopieprophylaxe
ATE117290T1 (de) * 1990-02-26 1995-02-15 R Tech Ueno Ltd 15-dehydroxy-16-oxoprostaglandine.

Also Published As

Publication number Publication date
DK0454429T3 (da) 1997-03-17
CA2041240A1 (en) 1991-10-28
EP0454429A3 (en) 1992-07-15
EP0454429A2 (en) 1991-10-30
KR910018028A (ko) 1991-11-30
AU639322B2 (en) 1993-07-22
AU7593091A (en) 1991-11-07
JPH04330015A (ja) 1992-11-18
CA2041240C (en) 2001-07-31
EP0454429B1 (en) 1997-01-29
ATE148344T1 (de) 1997-02-15
JPH07103030B2 (ja) 1995-11-08
KR970005173B1 (ko) 1997-04-14
DE69124415D1 (de) 1997-03-13
DE69124415T2 (de) 1997-05-15
GR3022706T3 (en) 1997-05-31

Similar Documents

Publication Publication Date Title
ATE169219T1 (de) Behandlung von katarakt mit 15-keto- prostaglandinderivaten
ATE82121T1 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
FI913045A0 (fi) Heterocyklenderivat.
FI875326A7 (fi) Valonsäteilyttäjälaite korvan lääketieteelliseen hoitoon.
ATE174221T1 (de) Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
FI933902A7 (fi) Substituoidut sykloheksaanijohdannaiset sairauksien hoitamiseksi
ES2089136T3 (es) Tratamiento de enfermedades inflamatorias con la ayuda de derivados 15-ceto-prostaglandinas.
ES2093774T3 (es) Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
NO911429D0 (no) Stoffbehandling.
DE69024744D1 (de) Behandlung der hepatobilären Erkrankung mit 15-Ketoprostaglandin-Derivaten
ES2099736T3 (es) Utilizacion de derivados de la 15-deshidroxi-16-oxoprostaglandina en el tratamiento de las alergias.
DE69032000D1 (de) Behandlung kardialer Dysfunktion mit 15-Ketoprostaglandinderivaten
DK0617959T3 (da) Lægemiddel til behandling af hudsygdomme
FI925544A7 (fi) Bentsoehappojohdannaisia leukotrieeniin liittyvien sairauksien hoitami seen
ATE129895T1 (de) Behandlung von pulmonarer disfunktion mit 15-keto-prostaglandin-derivaten.
NO911430D0 (no) Stoffbehandlingsmetode.
DE69100171D1 (de) Synergistische kombination zur ophthalmischen verwendung.
FI925546A7 (fi) Amidiliittyneitä pyridyylihappojohdannaisia leukotrieeniin liittyvien sairauksien hoitamiseksi
ES2098325T3 (es) Tratamiento de cataratas con compuestos de prostaciclina.
ATE90565T1 (de) Behandlung des schocks mit cyclodextrin und dessen derivaten.
ES2039255T3 (es) Utilizacion de n-((1-etil-2-pirrolidinil)metil)-2-metoxi-5-sulfamoil-benzamida en el tratamiento de la esterilidad.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 454429

Country of ref document: ES